We are live on ! Find out more
GRTX

Galera Therapeutics, Inc. Common Stock
GRTX

Delisted

GRTX was delisted on the 3rd of June, 2024.

Back to rankings

44 hedge funds and large institutions have $170M invested in Galera Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

27% more capital invested

Capital invested by funds: $134M → $170M (+$36.2M)

7% more funds holding

Funds holding: 41 → 44 (+3)

50% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 14

Holders
44
Holders Change
+3
Holders Change %
+7.32%
% of All Funds
0.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
14
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
+$409K
2
Millennium Management
Millennium Management
New York
+$221K
3
BlackRock
BlackRock
New York
+$202K
4
Russell Investments Group
Russell Investments Group
United Kingdom
+$176K
5
Goldman Sachs
Goldman Sachs
New York
+$167K

Top Sellers

Rank Fund Capital Flow
1
IM
Islet Management
New York
-$418K
2
Wells Fargo
Wells Fargo
California
-$74.5K
3
Renaissance Technologies
Renaissance Technologies
New York
-$71.2K
4
Morgan Stanley
Morgan Stanley
New York
-$23.9K
5
State Street
State Street
Massachusetts
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$39.4M – – –
NHAS
2
Novo Holdings A/S
Denmark
$30.8M – – –
SI
3
Sofinnova Investments
California
$27.9M – – –
Blackstone Inc
4
Blackstone Inc
New York
$15.2M – – –
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$13.6M – – –
TCM
6
Tekla Capital Management
Massachusetts
$9.42M – – –
RCM
7
RA Capital Management
Massachusetts
$7.46M – – –
RSCM
8
Rock Springs Capital Management
Maryland
$5.13M – – –
SFM
9
Sphera Funds Management
Israel
$4.24M – – –
BlackRock
10
BlackRock
New York
$3.82M +$202K +25,463 +6%
Vanguard Group
11
Vanguard Group
Pennsylvania
$3.32M -$9.35K -1,180 -0.3%
PA
12
Perceptive Advisors
New York
$2.94M – – –
Northern Trust
13
Northern Trust
Illinois
$940K -$1.9K -240 -0.2%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$918K +$58.7K +7,413 +8%
State Street
15
State Street
Massachusetts
$748K -$21K -2,649 -3%
WMSA
16
Weiss Multi-Strategy Advisers
New York
$613K +$125K +15,822 +30%
TWMP
17
Taylor Wealth Management Partners
Massachusetts
$562K +$17.8K +2,241 +4%
VA
18
VR Adviser
New York
$467K +$409K +51,653 New
Jacobs Levy Equity Management
19
Jacobs Levy Equity Management
New Jersey
$317K -$8.97K -1,133 -3%
RJFSA
20
Raymond James Financial Services Advisors
Florida
$258K – – –
Bank of New York Mellon
21
Bank of New York Mellon
New York
$218K – – –
Russell Investments Group
22
Russell Investments Group
United Kingdom
$201K +$176K +22,262 New
Goldman Sachs
23
Goldman Sachs
New York
$191K +$167K +21,106 New
Charles Schwab
24
Charles Schwab
California
$171K – – –
N
25
Nuveen
North Carolina
$127K – – –
1
2

GRTX Hedge Fund Activity: Q3 2020 in Review

44 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q3 2020, worth a combined $170M — up 27% from $134M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new GRTX positions and 2 closed out — a net gain of 3 holders — while 7 added to existing stakes and 14 trimmed.

The largest buyer was VR Adviser, opening a new position worth an estimated $409K. The largest seller was Islet Management, exiting entirely with an estimated $418K sold.

  • 44 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q3 2020, up from 41 in Q2 2020.
  • Funds reported $170M of Galera Therapeutics, Inc. Common Stock stock for Q3 2020, up 27% quarter-over-quarter.
  • 5 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q3 2020 and 2 closed out, a net change of +3 holders.
  • The largest Galera Therapeutics, Inc. Common Stock buyer in Q3 2020 was VR Adviser, an estimated $409K added.
  • The largest Galera Therapeutics, Inc. Common Stock seller in Q3 2020 was Islet Management, an estimated $418K sold.

Based on aggregated 13F filings for Q3 2020.